Repligen Operating Margin from 2010 to 2026

RGEN Stock  USD 136.44  3.81  2.87%   
Repligen Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to drop to -0.05.
Check Repligen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repligen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 104.5 M, Interest Expense of 21.3 M or Total Revenue of 766 M, as well as many indicators such as Price To Sales Ratio of 10.05, Dividend Yield of 0.0 or PTB Ratio of 2.9. Repligen financial statements analysis is a perfect complement when working with Repligen Valuation or Volatility modules.
  
Build AI portfolio with Repligen Stock
Check out the analysis of Repligen Correlation against competitors.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.
Evaluating Repligen's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Repligen's fundamental strength.

Latest Repligen's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Repligen over the last few years. It is Repligen's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repligen's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.07 %10 Years Trend
Very volatile
   Operating Profit Margin   
       Timeline  

Repligen Operating Margin Regression Statistics

Arithmetic Mean0.09
Geometric Mean0.15
Coefficient Of Variation255.79
Mean Deviation0.14
Median0.15
Standard Deviation0.23
Sample Variance0.05
Range1.03
R-Value0.09
Mean Square Error0.06
R-Squared0.01
Significance0.72
Slope0
Total Sum of Squares0.85

Repligen Operating Margin History

2026 -0.0523
2025 -0.0498
2024 -0.0553
2023 0.0754
2022 0.28
2021 0.25
2020 0.22

About Repligen Financial Statements

Repligen investors utilize fundamental indicators, such as Operating Margin, to predict how Repligen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.

Pair Trading with Repligen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Repligen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Repligen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Repligen Stock

  0.63A Agilent Technologies Earnings Call This WeekPairCorr

Moving against Repligen Stock

  0.56CTE Cryosite Earnings Call This WeekPairCorr
  0.51OBD Oxford Biodynamics PLCPairCorr
The ability to find closely correlated positions to Repligen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Repligen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Repligen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Repligen to buy it.
The correlation of Repligen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Repligen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Repligen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Repligen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:
Check out the analysis of Repligen Correlation against competitors.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Life Sciences Tools & Services sector continue expanding? Could Repligen diversify its offerings? Factors like these will boost the valuation of Repligen. Anticipated expansion of Repligen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Repligen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.6
Earnings Share
0.01
Revenue Per Share
12.602
Quarterly Revenue Growth
0.219
Return On Assets
0.013
Investors evaluate Repligen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Repligen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Repligen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Repligen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Repligen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Repligen's market price signifies the transaction level at which participants voluntarily complete trades.